EUVIMEDEUVIMED entdecken
Crossref

NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

Guo Li, Yongxiao Xu, Xiaojie Kong, Liuwei Gu, Yuling Qin, Li Wu

Chemical Communications · 2023

DOI: 10.1039/d3cc00663h ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Communications, 2023. Verfasst von Guo Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nantong Key Laboratory of Public Health and Medical Analysis, School of Public Health, Nantong University, No. 9, Seyuan Road, Nantong 226019, Jiangs…. Hauptthemen laut MEDLINE: Neoplasms, Prodrugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Excellent Youth Foundation of Jiangsu Scientific Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An NQO1-responsive agonist has been developed to evoke an anti-tumor immune response, providing a new concept for tumor-microenvironment-responsive prodrug design to achieve precise immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProdrugsHumansNADToll-Like Receptor 7NAD(P)H Dehydrogenase (Quinone)QuinonesTumor Microenvironment

Substanzen

NADToll-Like Receptor 7NAD(P)H Dehydrogenase (Quinone)ProdrugsQuinones

Autor:innen und Institutionen

  • Nantong Key Laboratory of Public Health and Medical Analysis, School of Public Health, Nantong University, No. 9, Seyuan Road, Nantong 226019, Jiangsu, P. R. China. ylqin@ntu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Excellent Youth Foundation of Jiangsu Scientific Committee

Zitieren

APA

Li, G., Xu, Y., Kong, X., Gu, L., Qin, Y., & Wu, L. (2023). NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy. Chemical Communications. https://doi.org/10.1039/d3cc00663h

Vancouver

Li G, Xu Y, Kong X, Gu L, Qin Y, Wu L. NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy. Chemical Communications. 2023. doi:10.1039/d3cc00663h

BibTeX
@article{Li2023,
  author = {Li, Guo and Xu, Yongxiao and Kong, Xiaojie and Gu, Liuwei and Qin, Yuling and Wu, Li},
  title = {NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy},
  journal = {Chemical Communications},
  year = {2023},
  doi = {10.1039/d3cc00663h}
}
Kostenlos starten →